These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 18932097)

  • 61. Antiangiogenic Targets for Glioblastoma Therapy from a Pre-Clinical Approach, Using Nanoformulations.
    Nery de Albuquerque Rego G; da Hora Alves A; Penteado Nucci M; Bustamante Mamani J; Anselmo de Oliveira F; Gamarra LF
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32599834
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Anti-angiogenic strategies in glioblastoma].
    Guillamo JS
    Rev Neurol (Paris); 2011 Oct; 167(10):662-7. PubMed ID: 21889779
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Bevacizumab for newly diagnosed glioblastoma.
    Chinot OL; Wick W; Cloughesy T
    N Engl J Med; 2014 May; 370(21):2049. PubMed ID: 24860870
    [No Abstract]   [Full Text] [Related]  

  • 64. Bevacizumab for newly diagnosed glioblastoma.
    Haines IE; Gabor Miklos GL
    N Engl J Med; 2014 May; 370(21):2048. PubMed ID: 24849089
    [No Abstract]   [Full Text] [Related]  

  • 65. Acneiform eruption in a patient receiving bevacizumab for glioblastoma multiforme.
    Keenan BP; Abuav R
    Arch Dermatol; 2010 May; 146(5):577. PubMed ID: 20479324
    [No Abstract]   [Full Text] [Related]  

  • 66. Questions regarding the optimal use of bevacizumab in glioblastoma: a moving target.
    Stupp R; Weller M
    Neuro Oncol; 2014 Jun; 16(6):765-7. PubMed ID: 24826844
    [No Abstract]   [Full Text] [Related]  

  • 67. Current status of antiangiogenic therapies for glioblastomas.
    Arrillaga-Romany I; Reardon DA; Wen PY
    Expert Opin Investig Drugs; 2014 Feb; 23(2):199-210. PubMed ID: 24320142
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The new cancer blockers.
    Johns Hopkins Med Lett Health After 50; 2004 Oct; 17(8):1-2, 7. PubMed ID: 15602777
    [No Abstract]   [Full Text] [Related]  

  • 69. [Bevacizumab].
    Taéron C
    Rev Infirm; 2009; (147):46-8. PubMed ID: 19317091
    [No Abstract]   [Full Text] [Related]  

  • 70. Bevacizumab for newly diagnosed glioblastoma.
    Gilbert MR; Sulman EP; Mehta MP
    N Engl J Med; 2014 May; 370(21):2048-9. PubMed ID: 24849088
    [No Abstract]   [Full Text] [Related]  

  • 71. Predicting glioblastoma response to bevacizumab through marker profiling?
    Kessler T
    Neuro Oncol; 2016 Feb; 18(2):149-50. PubMed ID: 26803809
    [No Abstract]   [Full Text] [Related]  

  • 72. Antiangiogenic Therapy of High-Grade Gliomas.
    Jo J; Wen PY
    Prog Neurol Surg; 2018; 31():180-199. PubMed ID: 29393186
    [TBL] [Abstract][Full Text] [Related]  

  • 73. A multilayer grow-or-go model for GBM: effects of invasive cells and anti-angiogenesis on growth.
    Saut O; Lagaert JB; Colin T; Fathallah-Shaykh HM
    Bull Math Biol; 2014 Sep; 76(9):2306-33. PubMed ID: 25149139
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Update on bevacizumab and other angiogenesis inhibitors for brain cancer.
    Rinne ML; Lee EQ; Nayak L; Norden AD; Beroukhim R; Wen PY; Reardon DA
    Expert Opin Emerg Drugs; 2013 Jun; 18(2):137-53. PubMed ID: 23668489
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The glioblastoma vasculature as a target for cancer therapy.
    Dimberg A
    Biochem Soc Trans; 2014 Dec; 42(6):1647-52. PubMed ID: 25399584
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Antiangiogenic Therapy for Malignant Brain Tumors: Does It Still Matter?
    Pellerino A; Bruno F; Soffietti R; Rudà R
    Curr Oncol Rep; 2023 Jul; 25(7):777-785. PubMed ID: 37071295
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Treatment of glioblastoma with bevacizumab: has a new standard therapy been defined?
    Chamberlain MC
    CNS Drugs; 2011 Oct; 25(10):815-8. PubMed ID: 21936584
    [No Abstract]   [Full Text] [Related]  

  • 78. The evolving role of antiangiogenic therapies in glioblastoma multiforme: current clinical significance and future potential.
    Anthony C; Mladkova-Suchy N; Adamson DC
    Expert Opin Investig Drugs; 2019 Sep; 28(9):787-797. PubMed ID: 31356114
    [No Abstract]   [Full Text] [Related]  

  • 79. Is deferred use of bevacizumab for glioblastoma associated with prolonged survival?
    D'Alessandris QG; Capo G; Pallini R
    Neuro Oncol; 2014 Oct; 16(10):1427. PubMed ID: 25053854
    [No Abstract]   [Full Text] [Related]  

  • 80. Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy.
    Piccioni DE; Lai A
    Neuro Oncol; 2014 Oct; 16(10):1427-8. PubMed ID: 25155359
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.